{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:09:21Z","timestamp":1749683361435,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Gobierno Regional de Los R\u00edos","award":["FICR19-20"],"award-info":[{"award-number":["FICR19-20"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00467-022-05694-z","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T09:02:51Z","timestamp":1660554171000},"page":"1195-1203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl"],"prefix":"10.1007","volume":"38","author":[{"given":"Carla","family":"Galvez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Krall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4425-7193","authenticated-orcid":false,"given":"Francisco","family":"Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"5694_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/IJNRD.S41837","volume":"7","author":"S Grisaru","year":"2014","unstructured":"Grisaru S (2014) Management of hemolytic-uremic syndrome in children. Int J Nephrol Renovasc Dis 7:231\u2013239. https:\/\/doi.org\/10.2147\/IJNRD.S41837","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"5694_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/S0140-6736(05)71144-2","volume":"365","author":"PI Tarr","year":"2005","unstructured":"Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073\u20131086. https:\/\/doi.org\/10.1016\/S0140-6736(05)71144-2","journal-title":"Lancet"},{"key":"5694_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/archdischild-2016-311377","volume":"103","author":"PR Walsh","year":"2018","unstructured":"Walsh PR, Johnson S (2018) Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child 103:285\u2013291. https:\/\/doi.org\/10.1136\/archdischild-2016-311377","journal-title":"Arch Dis Child"},{"key":"5694_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D (2018) Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 13:300\u2013317. https:\/\/doi.org\/10.2215\/CJN.00620117","journal-title":"Clin J Am Soc Nephrol"},{"key":"5694_CR5","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00467-018-3903-9","volume":"33","author":"L Percheron","year":"2018","unstructured":"Percheron L, Gramada R, Tellier S, Salomon R, Harambat J, Llanas B, Fila M, Allain-Launay E, Lapeyraque AL, Leroy V, Adra AL, B\u00e9rard E, Bourdat-Michel G, Chehade H, Eckart P, Merieau E, Pi\u00e8trement C, Sellier-Leclerc AL, Fr\u00e9meaux-Bacchi V, Dimeglio C, Garnier A\u00a0(2018) Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 33:1385\u20131394. https:\/\/doi.org\/10.1007\/s00467-018-3903-9","journal-title":"Pediatr Nephrol"},{"key":"5694_CR6","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00467-013-2561-1","volume":"29","author":"LS Keir","year":"2014","unstructured":"Keir LS, Saleem MA (2014) Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 29:1895\u20131902. https:\/\/doi.org\/10.1007\/s00467-013-2561-1","journal-title":"Pediatr Nephrol"},{"key":"5694_CR7","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3201\/EID1104.040833","volume":"11","author":"RM Lynn","year":"2005","unstructured":"Lynn RM, O\u2019Brien SJ, Taylor CM, Adak GK, Chart H, Cheasty T, Coia JE, Gillespie IA, Locking ME, Reilly WJ, Smith HR, Waters A, Willshaw GA (2005) Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 11:590\u2013596. https:\/\/doi.org\/10.3201\/EID1104.040833","journal-title":"Emerg Infect Dis"},{"key":"5694_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molimm.2013.11.009","volume":"58","author":"K Poolpol","year":"2014","unstructured":"Poolpol K, Orth-H\u00f6ller D, Speth C, Zipfel PF, Skerka C, de C\u00f3rdoba SR, Brockmeyer J, Bielaszewska M, W\u00fcrzner R (2014) Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Mol Immunol 58:77\u201384. https:\/\/doi.org\/10.1016\/j.molimm.2013.11.009","journal-title":"Mol Immunol"},{"key":"5694_CR9","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","volume":"28","author":"JM Spinale","year":"2013","unstructured":"Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS (2013) Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28:2097\u20132105. https:\/\/doi.org\/10.1007\/s00467-012-2383-6","journal-title":"Pediatr Nephrol"},{"key":"5694_CR10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1086\/341940","volume":"186","author":"A Gerber","year":"2002","unstructured":"Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB (2002) Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997\u20132000, in Germany and Austria: a prospective study. J Infect Dis 186:493\u2013500. https:\/\/doi.org\/10.1086\/341940","journal-title":"J Infect Dis"},{"key":"5694_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fr\u00e9meaux-Bacchi V; HUS International (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339. https:\/\/doi.org\/10.1007\/s00467-015-3076-8","journal-title":"Pediatr Nephrol"},{"key":"5694_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.5555\/uri:pii:0022214377900713","volume":"89","author":"Y Kim","year":"1977","unstructured":"Kim Y, Miller K, Michael AF (1977) Breakdown products of C3 and factor B in hemolytic-uremic syndrome. J Lab Clin Med 89:845\u2013850. https:\/\/doi.org\/10.5555\/uri:pii:0022214377900713","journal-title":"J Lab Clin Med"},{"key":"5694_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/EMMM.201100169","volume":"3","author":"D Orth-H\u00f6ller","year":"2011","unstructured":"Orth-H\u00f6ller D, Riedl M, W\u00fcrzner R (2011) Inhibition of terminal complement activation in severe Shiga toxin-associated HUS\u2014perfect example for a fast track from bench to bedside. EMBO Mol Med 3:617\u2013619. https:\/\/doi.org\/10.1002\/EMMM.201100169","journal-title":"EMBO Mol Med"},{"key":"5694_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1055\/S-0034-1375295","volume":"40","author":"D Orth-H\u00f6ller","year":"2014","unstructured":"Orth-H\u00f6ller D, W\u00fcrzner R (2014) Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome. Semin Thromb Hemost 40:503\u2013507. https:\/\/doi.org\/10.1055\/S-0034-1375295","journal-title":"Semin Thromb Hemost"},{"key":"5694_CR15","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","volume":"182","author":"D Orth","year":"2009","unstructured":"Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, W\u00fcrzner R  (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182:6394\u20136400. https:\/\/doi.org\/10.4049\/jimmunol.0900151","journal-title":"J Immunol"},{"key":"5694_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/toxins13010008","volume":"13","author":"S Kellnerov\u00e1","year":"2020","unstructured":"Kellnerov\u00e1 S, Chatterjee S, Bayarri-Olmos R, Justesen L, Talasz H, Posch W, Kenno S, Garred P, Orth-H\u00f6ller D, Grasse M, W\u00fcrzner R (2020) Shiga toxin 2a binds to complement components C3b and C5 and upregulates their gene expression in human cell lines. Toxins (Basel) 13:8. https:\/\/doi.org\/10.3390\/toxins13010008","journal-title":"Toxins (Basel)"},{"key":"5694_CR17","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.4049\/jimmunol.1502377","volume":"197","author":"I Arvidsson","year":"2016","unstructured":"Arvidsson I, Rebetz J, Loos S, Hertelious M, Kristoffersson AC, Englund E, Chromek M, Karpman D  (2016) Early terminal complement blockade and C6 deficiency are protective in enterohemorrhagic Escherichia coli-infected mice. J Immunol 197:1276\u20131286. https:\/\/doi.org\/10.4049\/jimmunol.1502377","journal-title":"J Immunol"},{"key":"5694_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00467-017-3850-x","volume":"34","author":"C Zoja","year":"2019","unstructured":"Zoja C, Buelli S, Morigi M (2019) Shiga toxin triggers endothelial and podocyte injury: the role of complement activation. Pediatr Nephrol 34:379\u2013388. https:\/\/doi.org\/10.1007\/s00467-017-3850-x","journal-title":"Pediatr Nephrol"},{"key":"5694_CR19","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1128\/IAI.01079-12","volume":"81","author":"S Ehrlenbach","year":"2013","unstructured":"Ehrlenbach S, Rosales A, Posch W, Wilflingseder D, Hermann M, Brockmeyer J, Karch H, Satchell SC, W\u00fcrzner R, Orth-H\u00f6ller D (2013) Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immun 81:2678\u20132685. https:\/\/doi.org\/10.1128\/IAI.01079-12","journal-title":"Infect Immun"},{"key":"5694_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00467-019-04334-3","volume":"35","author":"A Balestracci","year":"2020","unstructured":"Balestracci A, Meni Bataglia L, Toledo I, Beaudoin L, Alvarado C (2020) C3 levels and acute outcomes in Shiga toxin\u2013related hemolytic uremic syndrome. Pediatr Nephrol 35:331\u2013339. https:\/\/doi.org\/10.1007\/s00467-019-04334-3","journal-title":"Pediatr Nephrol"},{"key":"5694_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fmed.2020.00357","volume":"7","author":"GS Netti","year":"2020","unstructured":"Netti GS, Santangelo L, Paulucci L, Piscopo G, Torres DD, Carbone V, Giordano P, Spadaccino F, Castellano G, Stallone G, Gesualdo L, Chironna M, Ranieri E, Giordano M  (2020) Low C3 serum levels predict severe forms of STEC-HUS with neurologic involvement. Front Med 7:357. https:\/\/doi.org\/10.3389\/fmed.2020.00357","journal-title":"Front Med"},{"key":"5694_CR22","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/nejmc1100859","volume":"364","author":"AL Lapeyraque","year":"2011","unstructured":"Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F (2011) Eculizumab in Severe Shiga-Toxin\u2013Associated HUS. N Eng J Med 364:2561\u20132563. https:\/\/doi.org\/10.1056\/nejmc1100859","journal-title":"N Eng J Med"},{"key":"5694_CR23","doi-asserted-by":"publisher","first-page":"e1000","DOI":"10.1097\/MD.0000000000001000","volume":"94","author":"L Pape","year":"2015","unstructured":"Pape L, Hartmann H, Bange Christoph Bange F, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T (2015) Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement. Medicine 94:e1000. https:\/\/doi.org\/10.1097\/MD.0000000000001000","journal-title":"Medicine"},{"key":"5694_CR24","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","volume":"27","author":"JT Kielstein","year":"2012","unstructured":"Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, N\u00fcrnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R; Collaborators of the DGfN STEC-HUS registry (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: An analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807\u20133815. https:\/\/doi.org\/10.1093\/ndt\/gfs394","journal-title":"Nephrol Dial Transplant"},{"key":"5694_CR25","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00467-018-4025-0","volume":"34","author":"PR Walsh","year":"2019","unstructured":"Walsh PR, Johnson S (2019) Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 34:1485\u20131492. https:\/\/doi.org\/10.1007\/s00467-018-4025-0","journal-title":"Pediatr Nephrol"},{"key":"5694_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00467-009-1306-7","volume":"25","author":"S De","year":"2010","unstructured":"De S, Waters AM, Segal AO, Trautmann A, Harvey EA, Licht C (2010) Severe atypical HUS caused by CFH S1191L-case presentation and review of treatment options. Pediatr Nephrol 25:97\u2013104. https:\/\/doi.org\/10.1007\/s00467-009-1306-7","journal-title":"Pediatr Nephrol"},{"key":"5694_CR27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/humu.9408","volume":"27","author":"S Heinen","year":"2006","unstructured":"Heinen S, Sanchez-Corral P, Jackson MS, Strain L, Goodship JA, Kemp EJ, Skerka C, Jokiranta TS, Meyers K, Wagner E, Robitaille P, Esparza-Gordillo J, Rodriguez de Cordoba S, Zipfel PF, Goodship TH (2006) De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 27:292\u2013293. https:\/\/doi.org\/10.1002\/humu.9408","journal-title":"Hum Mutat"},{"key":"5694_CR28","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2215\/CJN.05830518","volume":"14","author":"V Fr\u00e9meaux-Bacchi","year":"2019","unstructured":"Fr\u00e9meaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, Limou S, Kwon T, Lahoche A, Novo R, Llanas B, Nobili F, Roussey G, Cailliez M, Ulinski T, Desch\u00eanes G, Alberti C, Weill FX, Mariani P, Loirat C (2019) Complement gene variants and shiga toxin-producing escherichia coli-associated hemolytic uremic syndrome retrospective genetic and clinical study. Clin J Am Soc Nephrol 14:364\u2013377. https:\/\/doi.org\/10.2215\/CJN.05830518","journal-title":"Clin J Am Soc Nephrol"},{"key":"5694_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4049\/jimmunol.1100491","volume":"187","author":"M Morigi","year":"2011","unstructured":"Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C  (2011) Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187:172\u2013180. https:\/\/doi.org\/10.4049\/jimmunol.1100491","journal-title":"J Immunol"},{"key":"5694_CR30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000187063","volume":"62","author":"WLM Robson","year":"1992","unstructured":"Robson WLM, Leung AKC, Fick GH, McKenna AI (1992) Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 62:296\u2013299. https:\/\/doi.org\/10.1159\/000187063","journal-title":"Nephron"},{"key":"5694_CR31","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.2215\/CJN.02730409","volume":"4","author":"JM Thurman","year":"2009","unstructured":"Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H (2009) Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1920\u20131924. https:\/\/doi.org\/10.2215\/CJN.02730409","journal-title":"Clin J Am Soc Nephrol"},{"key":"5694_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/cei.12601","volume":"181","author":"JR Ferraris","year":"2015","unstructured":"Ferraris JR, Ferraris V, Acquier AB, Sorroche PB, Saez MS, Ginaca A, Mendez CF (2015) Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. Clin Exp Immunol 181:118\u2013125. https:\/\/doi.org\/10.1111\/cei.12601","journal-title":"Clin Exp Immunol"},{"key":"5694_CR33","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s00467-021-04988-y","volume":"36","author":"LF Alconcher","year":"2021","unstructured":"Alconcher LF, Balestracci A, Coccia PA, Suarez ADC, Ram\u00edrez FB, Monteverde ML, Perez Y Guti\u00e9rrez MG, Carlopio PM, Principi I, Estrella P, Micelli S, Leroy DC, Quijada NE, Seminara C, Giordano MI, Hidalgo Sol\u00eds SB, Saurit M, Caminitti A, Arias A, Liern M, Rivas M (2021) Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli infection in Argentina: update of serotypes and genotypes and their relationship with severity of the disease. Pediatr Nephrol 36:2811\u20132817. https:\/\/doi.org\/10.1007\/s00467-021-04988-y","journal-title":"Pediatr Nephrol"},{"key":"5694_CR34","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1007\/s00467-021-04965-5","volume":"36","author":"M Muff-Luett","year":"2021","unstructured":"Muff-Luett M, Sanderson KR, Engen RM, Zahr RS, Wenderfer SE, Tran CL, Sharma S, Cai Y, Ingraham S, Winnicki E, Weaver DJ, Hunley TE, Kiessling SG, Seamon M, Woroniecki R, Miyashita Y, Xiao N, Omoloja AA, Kizilbash SJ, Mansuri A, Kallash M, Yu Y, Sherman AK, Srivastava T, Nester CM (2021) Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium study. Pediatr Nephrol 36:2349\u20132360. https:\/\/doi.org\/10.1007\/s00467-021-04965-5","journal-title":"Pediatr Nephrol"},{"key":"5694_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00228-016-2027-z","volume":"72","author":"J Casta\u00f1eda-Sanabria","year":"2016","unstructured":"Casta\u00f1eda-Sanabria J, Hajage D, le Jouan M, Perozziello A, Tubach F (2016) Off-label use of the expensive orphan drug eculizumab in France 2009\u20132013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol 72:737\u2013746. https:\/\/doi.org\/10.1007\/s00228-016-2027-z","journal-title":"Eur J Clin Pharmacol"},{"key":"5694_CR36","doi-asserted-by":"publisher","first-page":"e27913","DOI":"10.1002\/pbc.27913","volume":"66","author":"U Mahat","year":"2019","unstructured":"Mahat U, Matar RB, Rotz SJ (2019) Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence. Pediatr Blood Cancer 66:e27913. https:\/\/doi.org\/10.1002\/pbc.27913","journal-title":"Pediatr Blood Cancer"},{"key":"5694_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/DMCN.12161","volume":"55","author":"C Gitiaux","year":"2013","unstructured":"Gitiaux C, Krug P, Grevent D, Kossorotoff M, Poncet S, Eisermann M, Oualha M, Boddaert N, Salomon R, Desguerre I (2013) Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 55:758\u2013765. https:\/\/doi.org\/10.1111\/DMCN.12161","journal-title":"Dev Med Child Neurol"},{"key":"5694_CR38","doi-asserted-by":"publisher","unstructured":"Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenm\u00fcller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, M\u00fcnte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Sch\u00f6cklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellh\u00f6ner P, Wiesner M, Zeissig S, B\u00fcning J, Schiffer M, Kuehbacher T; EHEC-HUS consortium (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565. https:\/\/doi.org\/10.1136\/BMJ.E4565","DOI":"10.1136\/BMJ.E4565"},{"key":"5694_CR39","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s00467-022-05451-2","volume":"37","author":"R Raina","year":"2022","unstructured":"Raina R, Sethi S, Dragon-Durey M, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C  (2022) Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 37:1479\u20131493. https:\/\/doi.org\/10.1007\/s00467-022-05451-2","journal-title":"Pediatr Nephrol"},{"key":"5694_CR40","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","volume":"124","author":"M Noris","year":"2014","unstructured":"Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G  (2014) Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124:1715\u20131726. https:\/\/doi.org\/10.1182\/blood-2014-02-558296","journal-title":"Blood"},{"key":"5694_CR41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/CEI.12426","volume":"181","author":"EB Volokhina","year":"2015","unstructured":"Volokhina EB, Westra D, van der Velden TJAM, van de Kar NCAJ, Mollnes TE, van den Heuvel LP (2015) Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol 181:306\u2013313. https:\/\/doi.org\/10.1111\/CEI.12426","journal-title":"Clin Exp Immunol"},{"key":"5694_CR42","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/BLOOD-2013-12-547067","volume":"123","author":"SR Cataland","year":"2014","unstructured":"Cataland SR, Holers VM, Geyer S, Yang S, Wu HM (2014) Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 123:3733\u20133738. https:\/\/doi.org\/10.1182\/BLOOD-2013-12-547067","journal-title":"Blood"},{"key":"5694_CR43","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1053\/j.ajkd.2015.02.326","volume":"65","author":"F Bu","year":"2015","unstructured":"Bu F, Zhang Y, Thomas C, Smith RJH (2015) Soluble C5b\u20139 as a biomarker for complement activation in atypical hemolytic uremic syndrome. Am J Kidney Dis 65:968\u2013969. https:\/\/doi.org\/10.1053\/j.ajkd.2015.02.326","journal-title":"Am J Kidney Dis"},{"key":"5694_CR44","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/S00431-018-3255-2","volume":"177","author":"L Karnisova","year":"2018","unstructured":"Karnisova L, Hradsky O, Blahova K, Fencl F, Dolezel Z, Zaoral T, Zieg J (2018) Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study. Eur J Pediatr 177:1837\u20131844. https:\/\/doi.org\/10.1007\/S00431-018-3255-2","journal-title":"Eur J Pediatr"},{"key":"5694_CR45","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2215\/CJN.05830519","volume":"14","author":"M Palomo","year":"2022","unstructured":"Palomo M, Blasco M, Molina P, Losano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M (2022) Complement activation and thrombotic microangiopathies. Clin J Am Soc Nephrol 14:1719\u20131732. https:\/\/doi.org\/10.2215\/CJN.05830519","journal-title":"Clin J Am Soc Nephrol"},{"key":"5694_CR46","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/J.EKIR.2022.02.021","volume":"7","author":"F Fakhouri","year":"2022","unstructured":"Fakhouri F, Schwotzer N, Golshayan D, Fr\u00e9meaux-Bacchi V (2022) The Rational Use of Complement Inhibitors in Kidney Diseases. Kidney Int Rep 7:1165\u20131178. https:\/\/doi.org\/10.1016\/J.EKIR.2022.02.021","journal-title":"Kidney Int Rep"},{"key":"5694_CR47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.23750\/abm.v89i9-S.7911","volume":"89","author":"L Bianchi","year":"2018","unstructured":"Bianchi L, Gaiani F, Vincenzi F, Kayali S, Di Mario F, Leandro G, De' Angelis GL, Ruberto C (2018) Hemolytic uremic syndrome: Differential diagnosis with the onset of inflammatory bowel diseases. Acta Biomed 89:153\u2013157. https:\/\/doi.org\/10.23750\/abm.v89i9-S.7911","journal-title":"Acta Biomed"},{"key":"5694_CR48","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1055\/s-2007-965013","volume":"17","author":"AS de Buys Roessingh","year":"2007","unstructured":"de Buys Roessingh AS, de Lagausie P, Baudoin V, Loirat C, Aigrain Y (2007) Gastrointestinal complications of post-diarrheal hemolytic uremic syndrome. Eur J Pediatr Surg 17:328\u2013334. https:\/\/doi.org\/10.1055\/s-2007-965013","journal-title":"Eur J Pediatr Surg"},{"key":"5694_CR49","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andr\u00e9 JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fr\u00e9meaux-Bacchi V  (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180\u20132187. https:\/\/doi.org\/10.1681\/ASN.2010030315","journal-title":"J Am Soc Nephrol"},{"key":"5694_CR50","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1021\/BI201689J","volume":"51","author":"AP Herbert","year":"2012","unstructured":"Herbert AP, Kavanagh D, Johansson C, Morgan HP, Blaum BS, Hannan JP, Barlow PN, Uhr\u00edn D\u00a0(2012) Structural and functional characterization of the product of disease-related factor H gene conversion. Biochemistry 51:1874\u20131884. https:\/\/doi.org\/10.1021\/BI201689J","journal-title":"Biochemistry"},{"key":"5694_CR51","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1371\/journal.pmed.0030431","volume":"3","author":"JP Venables","year":"2006","unstructured":"Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A, Wood KM, Goodship JA, Goodship TH (2006) Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 3:1957\u20131967. https:\/\/doi.org\/10.1371\/journal.pmed.0030431","journal-title":"PLoS Med"},{"key":"5694_CR52","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1111\/j.1600-6143.2012.04051.x","volume":"12","author":"S Krid","year":"2012","unstructured":"Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Fr\u00e9meaux-Bacchi V, Niaudet P  (2012) Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH\/CFHR1 hybrid protein. Am J Transplant 12:1938\u20131944. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04051.x","journal-title":"Am J Transplant"},{"key":"5694_CR53","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.kint.2021.02.033","volume":"100","author":"RN Bouwmeester","year":"2021","unstructured":"Bouwmeester RN, van de Kar NCAJ, Wetzels JFM (2021) Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome. Kidney Int 100:265\u2013268. https:\/\/doi.org\/10.1016\/j.kint.2021.02.033","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"5694_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-136617","volume":"136","author":"A Acosta-Medina","year":"2020","unstructured":"Acosta-Medina A, Moyer A, Go R, Willrich MA, Alkhateeb HB, Chen D, Heikal NM, Leung N, Marshall AL, Tran CL, Winters JL, Sridharan M  (2020) Determination of relapse risk by complement gene variants after eculizumab discontinuation in complement-mediated thrombotic microangiopathy: a retrospective review. Blood 136(Suppl 1):25\u201326. https:\/\/doi.org\/10.1182\/blood-2020-136617","journal-title":"Blood"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05694-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05694-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05694-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T23:25:42Z","timestamp":1676330742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05694-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5694"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05694-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"type":"print","value":"0931-041X"},{"type":"electronic","value":"1432-198X"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}